ADAURA

TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer

Retrieved on: 
Friday, January 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cancer, Medicine, Cancer treatments, Adjuvant therapy, Non-small-cell lung carcinoma, Chemotherapy, Lung cancer, Osimertinib, Epidermal growth factor receptor, ADAURA, TAGRISSO

In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy.

Key Points: 
  • In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy.
  • If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity
    Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO.
  • Adjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer: Where is it Going?
  • EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples.

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

Retrieved on: 
Monday, December 21, 2020
Other Health, Research, General Health, Pharmaceutical, Oncology, Clinical trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Lung cancer, Breakthrough therapy, Organic compounds, Chemical compounds, Health sciences, Acrylamides, Ethers, Osimertinib, Pyrimidines, Non-small-cell lung carcinoma, T790M, Other Health, Research, General Health, Pharmaceutical, Oncology, Clinical trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Lung cancer, Breakthrough therapy, Organic compounds, Chemical compounds, Health sciences, Acrylamides, Ethers, Osimertinib, Pyrimidines, Non-small-cell lung carcinoma, T790M, ADAURA, TAGRISSO

TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.

Key Points: 
  • TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.
  • We remain committed to treating cancer patients earlier, when they may still have a chance of being cured.
  • TAGRISSO was recently granted Breakthrough Therapy Designation for patients in the early-stage disease setting by the US FDA.
  • In China, TAGRISSO is under priority review for the adjuvant treatment of patients with early-stage EGFRm NSCLC based on the ADAURA Phase III trial.

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

Retrieved on: 
Saturday, September 19, 2020
Oncology, Health, FDA, General Health, Clinical trials, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Clinical medicine, Lung cancer, Indoles, RTT, Breakthrough therapy, Ethers, Osimertinib, Heart failure, Keratitis, Lung cancer, ADAURA, TAGRISSO

Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.

Key Points: 
  • Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
  • For symptomatic congestive heart failure, permanently discontinue TAGRISSO
    Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials.
  • Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
    Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO.
  • Patients were treated with TAGRISSO 80 mg once-daily oral tablets or placebo for three years or until disease recurrence.

TAGRISSO Granted Breakthrough Therapy Designation in the US for the Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer

Retrieved on: 
Thursday, July 30, 2020
Research, FDA, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Health, Organic compounds, Chemical compounds, Lung cancer, Aging-associated diseases, Clinical endpoint, Clinical research, Heart failure, Osimertinib, lung cancer, ADAURA, TAGRISSO, AstraZeneca

Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.

Key Points: 
  • Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
  • For symptomatic congestive heart failure, permanently discontinue TAGRISSO
    Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials.
  • Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose.
  • The primary endpoint is DFS in Stage II and IIIA patients and a key secondary endpoint is DFS in Stage IB, II and IIIA patients.

TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer

Retrieved on: 
Thursday, May 28, 2020
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Cancer treatments, Lung cancer, Oncology, Adjuvant therapy, Analgesics, Osimertinib, Chemotherapy, Keratitis, lung cancer, ADAURA, TAGRISSO, AstraZeneca

For symptomatic congestive heart failure, permanently discontinue TAGRISSO

Key Points: 
  • For symptomatic congestive heart failure, permanently discontinue TAGRISSO
    Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials.
  • Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
    Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO.
  • Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose.
  • Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?